Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.
Researchers have developed a non-addictive painkiller that remains inactive until it reaches sites of chronic pain. Instead of dulling the nerves that send the pain signals like other analgesics, this ...
The objective of this study was to review medical publications in English, Spanish and Portuguese, in the last ten years, about painful peripheral neuropathy. Although limited reliable evidence ...